Frankfurter Rundschau: NAD+ Levels Stable in Healthy Adults; NOPARK Trial Shows No Benefit in Parkinson’s

A new analysis of blood samples from more than 1,000 adults found no general age-related decline in NAD+ levels, undercutting the central premise driving a global supplement market.

Frankfurter Rundschau reported that the NOPARK trial in Norway even saw a statistically significant worsening of motor symptoms in the NR group compared to placebo, though the difference fell below the threshold for clinical relevance.

“The study creates important clarity in a field full of contradictory reports, hype and commercial promises,” wrote the authors of the Amsterdam UMC-led blood analysis, led by Maria Trętowicz and Riekelt Houtkooper, according to Fr. Their team evaluated seven independent datasets covering over 300 individuals, from frail elderly to elite athletes, and found stable NAD+ levels in healthy men across age groups and a slight increase in healthy women.

Lower values appeared primarily in participants with cardiovascular disease, though the direction of causality remains unclear. Wissenschaftswelle said that the research used dried blood spots from 1,068 adults collected after an overnight fast, measuring total NAD (NAD+ plus NADH).

Frankfurter Rundschau: NAD+ Levels Stable in Healthy Adults; NOPARK Trial Shows No Benefit in Parkinson's
Photo: wissenschaftswelle.de

Blood NAD+ Levels Do Not Decline with Age

  • Blood levels are not dropping with age. The core marketing claim—that NAD+ halves by middle age—is not supported by current population-level blood data.
  • Supplements raise blood markers, not health outcomes. Multiple 2026 trials confirm NR and NMN reliably increase circulating NAD+, but failed to improve mobility, cognition, or disease progression.
  • Brain delivery remains unproven.

The Parkinson’s Trial That Shifted the Narrative

The NOPARK study, published in October in JAMA, remains the most definitive test of an NAD+ booster in neurodegeneration. Researchers at the University of Bergen enrolled 410 patients with early Parkinson’s disease across 11 Norwegian clinics. Participants received 500 mg of NR twice daily or a matching placebo for 52 weeks.

The primary endpoint—change in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I-III—worsened by 2.72 points more in the NR group than in the placebo group. While statistically significant, the difference did not meet the pre-specified threshold for clinical meaningfulness. Non-motor symptoms also trended worse with NR. Serious adverse events were balanced between arms.

Crucially, while plasma NAD+ rose substantially, magnetic resonance spectroscopy detected no change in brain NAD+ after one year. “The research team advises Parkinson’s patients against taking NR or other NAD+ boosters outside of controlled studies,” Frankfurter Rundschau reported, citing the investigators led by Charalampos Tzoulis.

Healthy Aging and Cognition: No Signal in Two Further Trials

In July, Alzheimer’s & Dementia published a 12-week University of Delaware trial of NR in older adults with mild cognitive impairment. Blood NAD+ increased, yet standardized memory batteries, cardiovascular function, and global cerebral blood flow showed no improvement. A single signal—enhanced perfusion in the hippocampus—was noted as exploratory.

The University of Bergen, Norway’s second-oldest university, was established by an act of parliament in 1946 after consolidating scientific institutions dating back to 1825.

It operates as a public research university with over 4,000 employees and 19,000 students as of 2021, and is recognized as one of the country’s four “established universities” authorized to offer professional degrees in medicine and law. It is also a leader in marine and climate research, fields that align with its strategic focus on global challenges.

Where the Science Goes Next

As Houtkooper told the New York Times, he sees no reason for healthy people to take NAD+ precursors based on current evidence.

Parkinson's Disease: Potential Harm from Supplements

  • Parkinson’s disease: Clinical trial data suggests potential for harm (worsening motor scores) without proven benefit.

References

  • Trętowicz M, et al. 2026; DOI: 10.1038/s42255-026-01660-3 (Blood NAD+ cross-sectional analysis).
  • Tzoulis C, et al. 2026;326(14):1389-1398. (NOPARK trial).
  • Igarashi M, et al. 2026; (NMN in healthy seniors).
  • Martens CR, et al. 2026; DOI: 10.1002/alz.13876 (NR in mild cognitive impairment).
  • Dollerup OL, et al. 2026; DOI: 10.1038/s42255-025-01421-8 (Nestlé-led NR vs NMN bioavailability).
Photo of author

Health Desk

Health Desk at Archyde.

NATO Turkish Jets Scrambled in Estonia, Finland Restricts Eastern Gulf of Finland After Drone Threat